Appointments of VP of Sales, CTO, CFO and Chairman strengthens the Manus team, broadening the skillsets and expertise of the Group

Edinburgh, UK – 1st of June 2023: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces it has expanded its Senior Management team with the appointments of VP of Sales, Roberto Marcucci, Chief Technology Officer, Dr David Bramwell, Chief Financial Officer, Phil Pattison and Chairman, Albert Nicholl. Roberto Marcucci, … Read more

Agreement signed with Medispa to integrate NeuroMotor PenTM into Prevention Suite

Prevention Suite platform used by more than 10,000 pharmacies in Italy, Spain and Portugal. Partnership to be showcased at the annual Cosmofarma Exhibition in Bologna, Italy this weekend Edinburgh, UK – 5 May 2023: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces it has signed an agreement with … Read more

Agreement with Johnson & Johnson to use Neuromotor PenTM to detect neuromotor ad-verse effects following CAR T-cell therapy

Manus named awardee in ‘Improving Detection of Neurotoxicity in Immunotherapies’ QuickFire Challenge Edinburgh, UK – 24 April 2023: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces that it has been named an awardee in the ‘Improving Detection of Neurotoxicity in Immunotherapies’ QuickFire Challenge managed by Johnson & Johnson … Read more

FDA grants Breakthrough Device Designation for the Manus NeuroMotor Pen™

Designation provides priority regulatory review of the Manus NeuroMotor Pen™ designed to aid the diagnoses of Parkinson’s Disease Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces that it has been granted Breakthrough Designation by the U.S. Food and Drug Administration (“FDA”) for its Neuro-Motor PenTM (“NMP”) device. Breakthrough … Read more

Revolutionary non-invasive technology supporting early diagnosis of Parkinson’s disease showcased at MEDICA 2021

ABHI Medica

Manus Neurodynamica Limited (“Manus”), who develop and market products and technologies for neuromotor assessment, will be joining the ABHI UK Pavilion at MEDICA 2021 (15 – 18 November 2021) to launch their revolutionary non-invasive technology that supports an earlier and more accurate diagnosis of dementias and cognitive impairment. The NeuroMotor Pen (NMP) is a unique, … Read more

ISO Certification of Quality Management System

Validates Manus as a medical device company allowing the Company to fully engage in commercial activities Edinburgh, UK – 17 June 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces that it has received ISO 13485:2016 certification following an assessment of its Quality Management System (“QMS”), validating the … Read more

£600k grant funding from Innovate UK To validate the NeuroMotor PenTM for screening of dementias and cognitive im-pairment

Edinburgh, UK – 20 April 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, has received £600,000 grant funding from Innovate UK, to optimise and validate the NeuroMotor PenTM (NMP) for screening of dementias and cognitive impairment, over a two-year project. Only around 68% of over 65s, estimated to … Read more

Ex-Siemens Business Development Manager joins Manus

Manus Neurodynamica Limited Ex-Siemens Business Development Manager joins Manus Director of Commercial Growth appointed to execute sales and marketing strategy Edinburgh, UK – 18 March 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces the appointment of Euan Donald as Director of Commercial Growth with immediate effect, where … Read more

MANUS NEURODYNAMICA LIMITED NeuroMotor Pen™ Differentiates Parkinson’s from other tremors; Regulatory submission in the USA

Edinburgh, UK – 16 February 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces the results of a clinical study to validate the Manus system’s ability to distinguish Parkinson’s Disease (PD) from other movement disorders. The study was conducted at Northumbria Healthcare NHS Foundation Trust, North Shields, UK, … Read more